Pharmacy Times

DECEMBER 3, 2024

Promoting antimicrobial stewardship and providing patient education are examples of strategies to prevent antimicrobial resistance.

Pharma Marketing Network

DECEMBER 5, 2024

Table of Contents Sr# Headings 1 Introduction: The Power of Marketing Networks 2 What Are Marketing Networks? 3 The Importance of Marketing Networks in Pharma 4 Building Healthcare Professional (HCP) Networks 5 Patient Advocacy Groups: A Trusted Connection 6 Digital Marketing Networks in Pharma 7 Branded Campaigns and Marketing Networks 8 Overcoming Challenges in Marketing Networks 9 The Role of Data in Strengthening Networks 10 Future Trends in Marketing Networks 11 Practical Tips for Pharma Ma

Communication

European Pharmaceutical Review

DECEMBER 4, 2024

A new report, ‘ Enhancing the role of UK medicine regulation ’ by the Association of the British Pharmaceutical Industry (ABPI) explores the key role that regulatory excellence has in driving innovation and early treatment access for patients, as well bringing investment into the UK. It provides key recommendations aimed at rebuilding the UK’s world-class reputation in regulatory science, medicines’ development and licensing, driving economic growth, ensuring earlier patient access to innovative

Communication

The Checkup by Singlecare

DECEMBER 2, 2024

Combivent Respimat is a combination of the drugs albuterol and ipratropium, commonly prescribed to treat chronic obstructive pulmonary disease (COPD)—a group of pulmonary medical conditions (like chronic bronchitis) that make breathing difficult. As a bronchodilator, Combivent Respimat comes in an inhaler and can help open constricted airways. It can sometimes be expensive, and although there are no over-the-counter or generic versions, there are still some potentially cheaper alternatives.

Insurance

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Compounding Pharmacy of America

DECEMBER 6, 2024

Erectile dysfunction (ED) is often misunderstood as simply a sexual health concern, but it can signify much more. While many men experience occasional difficulties with sexual performance, persistent ED can be an early warning sign of serious underlying health issues such as cardiovascular disease, diabetes, or hormonal imbalances. Addressing ED is not just about improving […] The post Dont Ignore Erectile Dysfunction appeared first on Compounding Pharmacy of America.

Compounding Pharmacies

Pharma Marketing Network

DECEMBER 4, 2024

Table of Contents Sr# Headings 1 Introduction 2 Digital Transformation in Pharma Marketing 3 Patient-Centric Marketing 4 Personalized Healthcare Campaigns 5 The Role of AI and Machine Learning 6 Leveraging Social Media Platforms 7 Data-Driven Decision Making 8 Omnichannel Marketing Strategies 9 The Power of Influencer Marketing 10 Navigating Regulatory Challenges 11 Sustainability in Pharma Marketing 12 Conclusion 13 FAQs Introduction Pharma marketing is undergoing a revolution.

Communication

The Checkup by Singlecare

DECEMBER 2, 2024

An idea to use berberine along with metformin would not be unusual. Metformin forms the foundation of treatment for Type 2 diabetes mellitus. It is a first-line drug for diabetes because it not only controls blood glucose levels but also assists with weight loss and obesity management efforts. By helping our bodies be more sensitive to insulin, this generic pill can make a world of difference for those with diabetes and has been put to use off-label for prediabetes , polycystic ovary syndrome (

Dosage

STAT

DECEMBER 6, 2024

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay $16.5 billion for Catalent, a leading contract drug manufacturer. By taking this step, the executive arm of the European Union removed a significant obstacle to a deal that has generated debate over the extent to which competition in the pharmaceutical industry may be hindered.

Pharmaceutical Companies

Fierce Pharma

DECEMBER 2, 2024

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date. | Sanofi is laying out roughly 1 billion euros ($1.04 billion) to establish a new production base in the Beijing Economic and Technological Development Zone. The new manufacturing site, which will become Sanofi’s fourth in China, is being designed to beef up local end-to-end insulin production.

European Pharmaceutical Review

DECEMBER 2, 2024

This report delves into the latest developments in sustainability impacting the pharmaceutical sector today. Inside, articles explore current key topics including regulation, manufacturing, green chemistry, digitalisation and clinical trials. Stay up to date with the latest developments in sustainability including articles on: The key regulatory frameworks impacting the pharmaceutical industry and the challenges and opportunities around their implementation How digitalisation can transform and

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Checkup by Singlecare

DECEMBER 6, 2024

Clonidine is a generic medication that treats hypertension (high blood pressure). Because clonidine works differently than other blood pressure medications, it also has several off-label uses including anxiety, insomnia, attention deficit hyperactivity disorder (ADHD), and alcohol withdrawal. Clonidine, also sold under the brand name Catapres, is available as a tablet and once-a-week skin patch.

Labelling

STAT

DECEMBER 4, 2024

LONDON — The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the greatest need as the country tries to adapt to new ways of treating obesity amid surging demand.  Health authorities in the U.K. recommend tirzepatide, sold there as Mounjaro, for people with a body mass index of more than 35 and at least one related health condition.

Fierce Pharma

DECEMBER 3, 2024

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.

European Pharmaceutical Review

DECEMBER 3, 2024

Novartis Pharmaceuticals Corporation (a subsidiary of Novartis AG), is set to collaborate with PTC Therapeutics to develop the potential first oral disease-modifying therapy for Huntington’s disease. The global license and collaboration agreement is focused on PTC Therapeutics’ PTC518 Huntington’s disease programme. PTC will receive $1.0 billion upfront.

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

The Checkup by Singlecare

DECEMBER 2, 2024

Pantoprazole is a type of drug called a proton pump inhibitor (PPI) and is often sold under the brand name Protonix. It’s used to treat damage to the esophagus caused by gastroesophageal reflux disease (GERD) and in the treatment of certain conditions where the stomach produces too much acid, like Zollinger-Ellison syndrome. It may also be used to treat stomach inflammation and ulcers.

Packaging

STAT

DECEMBER 4, 2024

Year after year, more Americans are affected by health care data breaches. Though health savings accounts, pharmacies, and major hospitals have all been attacked in 2024, a single data breach accounted for the vast majority of people’s data being exposed: Change Healthcare. Multiple times this year, lawmakers have questioned health care industry experts about why the massive and disruptive Change Healthcare breach was allowed to happen , and what the government should do to improve health

Hospitals

Fierce Pharma

DECEMBER 4, 2024

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down fresh foundations at its old stomping grounds in Denmark to bolster a c | Novo will invest 2.9 billion Danish kroner (roughly $409 million) to construct a new, 53,000-square-meter quality control laboratory in Hillerød, Denmark.

Med Ed 101

DECEMBER 1, 2024

I hope everyone had a Happy Thanksgiving! It’s my turn to give back to all of you! We’ve got something for everyone looking to learn more about medications or preparing for board exams! Pharmacist Board Certification – 25% Off! Use this discount code at checkout: Board25 BCPS Study Materials NAPLEX Study Materials BCMTMS Study Materials […] The post Cyber Monday/Black Friday Discounts!

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

DECEMBER 2, 2024

You’re staring at the ceiling in the middle of the night, counting sheep, but instead of lulling you into a peaceful slumber, they won’t stop jumping around in your mind. If you regularly struggle with sleep issues, finding the right solution can feel like finding a needle in a haystack. Pharmaceutical options such as benzodiazepines like diazepam and antidepressants like trazodone are sometimes used off-label to treat insomnia in adults.

Dosage

STAT

DECEMBER 5, 2024

Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom from the Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.

Fierce Pharma

DECEMBER 2, 2024

The FDA is investigating reports of patients develo | The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week. The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer.

FDA

Fierce Healthcare

DECEMBER 3, 2024

With the incoming Trump administration and a Republican-controlled Congress, significant policy shifts are expected for the healthcare industry, from changes to the Affordable Care Act, the tone at | Analysts with S&P Global Ratings don't expect a major ratings impact for healthcare companies over the near to intermediate term, but anticipate changes will be a net negative for the industry from a credit perspective.

The Checkup by Singlecare

DECEMBER 2, 2024

If you have ever thrown out your back , your healthcare provider may have prescribed medication—or a combination of medications—to get you moving again. Two popularly prescribed medications for this use, as well as other conditions that cause pain, inflammation, and muscle spasms, are cyclobenzaprine and meloxicam. Both drugs are approved by the Food and Drug Administration (FDA) but for different uses.

Dosage

STAT

DECEMBER 3, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Pharma vs Congress: The latest in telehealth talks Eli Lilly and Pfizer have responded to senators who pressed them to share the details of their online platforms LillyDirect and PfizerForAll , seeking to determine whether the pharma giants are violating the federal anti-kick

Fierce Pharma

DECEMBER 2, 2024

After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe. | The General Court of the European Union decided not to extend a suspension of the European Commission’s decision to revoke Ocaliva’s marketing authorization. In turn, Intercept's liver disease drug, which is marketed by Advanz Pharma overseas, has lost its EU approval.

Drug Topics

DECEMBER 5, 2024

The Affordable Care Act was passed in 2010 to make health care and prescription medicine more accessible. Did it succeed?

PharmaVoice

DECEMBER 4, 2024

Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.

FDA

STAT

DECEMBER 3, 2024

Swedish pharmaceutical company Orexo will no longer pursue an app for treating depression after many years of struggling to sell it. Orexo announced this week that it will no longer license the product, called Deprexis, from German manufacturer GAIA. The companies have worked together on Deprexis in the United States since 2020 and have deals for two other apps, including Modia, an app that provides psychosocial support to people being treated for opioid addiction.

Pharmaceutical Companies

Fierce Pharma

DECEMBER 4, 2024

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care Excellence (NICE) has laid out plans for an unprecedented phased rollout that | Roughly 220,000 people in England will be eligible for the drug during the three-year launch phase. Afterward, officials plan to open access to a wider group of obesity patients, which numbers in the millions in England.

Drug Topics

NOVEMBER 30, 2024

Steve Callahan, Senior Director of Advisory & Insights at MMIT, discussed out-of-pocket costs and the impact biosimilars are predicted to have for patients in the future.

PharmaVoice

DECEMBER 2, 2024

Intrinsic Medicines is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.

STAT

DECEMBER 3, 2024

Top of the morning to you, and a fine one it is. Clear blue skies and chilly breezes are wafting over the Pharmalot campus, where the official mascots are snoozing after waking the neighbors and foraging for their breakfast. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation.

Fierce Pharma

DECEMBER 4, 2024

AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the count | AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country.

Insurance